Towards Effective Antiviral Oral Therapy: Development of a Novel Self-Double Emulsifying Drug Delivery System for Improved Zanamivir Intestinal Permeability.
bioavailability
intestinal permeability
microemulsion
nanoemulsion
oral drug absorption
self-double emulsifying drug delivery system
zanamivir
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
received:
21
09
2023
revised:
11
10
2023
accepted:
13
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Self-double emulsifying drug delivery systems have the potential to enhance the intestinal permeability of drugs classified under the Biopharmaceutics Classification System (BCS) class III. One such example is the antiviral agent zanamivir, exhibiting suboptimal oral absorption (with a bioavailability range of 1-5%). To address this challenge, we have developed an innovative oral formulation for zanamivir: a self-double nanoemulsifying Winsor delivery system (SDNE-WDS) consisting of the microemulsion, which subsequently yields final double nanoemulsion (W
Identifiants
pubmed: 37896277
pii: pharmaceutics15102518
doi: 10.3390/pharmaceutics15102518
pmc: PMC10610354
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
AAPS J. 2009 Dec;11(4):740-6
pubmed: 19876745
Clin Microbiol Rev. 2016 Jul;29(3):695-747
pubmed: 27281742
J Control Release. 2020 May 10;321:669-709
pubmed: 32112856
Clin Pharmacol. 2017 Feb 23;9:29-38
pubmed: 28260952
Carbohydr Polym. 2016 Nov 5;152:658-664
pubmed: 27516316
J Control Release. 2011 Nov 30;152 Suppl 1:e2-4
pubmed: 22195851
Antimicrob Agents Chemother. 1998 Mar;42(3):647-53
pubmed: 9517946
Adv Drug Deliv Rev. 2000 Dec 6;45(1):1-4
pubmed: 11104893
Int J Nanomedicine. 2021 Jul 22;16:4959-4984
pubmed: 34326637
PLoS One. 2015 Feb 03;10(2):e0116502
pubmed: 25647086
Curr Drug Deliv. 2011 Jul;8(4):392-297
pubmed: 21235479
J Pharm Sci. 2018 Jun;107(6):1478-1488
pubmed: 29421214
Int J Pharm. 2022 Dec 15;629:122392
pubmed: 36379395
Drug Dev Ind Pharm. 2017 Feb;43(2):177-189
pubmed: 27998192
Front Pharmacol. 2015 Sep 30;6:219
pubmed: 26483690
Int J Pharm. 2015 Jan 15;478(1):60-69
pubmed: 25448568
Clin Transplant. 1996 Aug;10(4):364-73
pubmed: 8884110
J Colloid Interface Sci. 2012 Oct 1;383(1):177-83
pubmed: 22795950
Int J Pharm. 2011 May 16;409(1-2):245-51
pubmed: 21356300
Int J Pharm. 2015 Jul 15;489(1-2):304-10
pubmed: 25957705
Chem Pharm Bull (Tokyo). 1995 Aug;43(8):1412-5
pubmed: 7553988
Nature. 2011 Dec 07;480(7376):S9-10
pubmed: 22158299
AAPS J. 2017 May;19(3):806-813
pubmed: 28204967
Medicina (Kaunas). 2019 May 24;55(5):
pubmed: 31137751
Antiviral Res. 2013 May;98(2):174-85
pubmed: 23523943
Mol Pharm. 2010 Aug 2;7(4):1223-34
pubmed: 20536260
Eur J Pharm Sci. 2015 Feb 20;68:27-35
pubmed: 25497319
Mol Pharm. 2012 Jul 2;9(7):2009-16
pubmed: 22632106
Int J Pharm. 2014 Oct 1;473(1-2):316-25
pubmed: 25014370
Expert Rev Anti Infect Ther. 2005 Apr;3(2):191-9
pubmed: 15918777
Eur J Pharm Biopharm. 2018 Feb;123:1-8
pubmed: 29133172
Acta Pharm Sin B. 2019 Nov;9(6):1145-1162
pubmed: 31867161
J Pharm Sci. 2012 Sep;101(9):3360-80
pubmed: 22644939
Antivir Chem Chemother. 2010;21(2):53-70
pubmed: 21107015
Mol Pharm. 2011 Dec 5;8(6):2358-67
pubmed: 21905667
Biotechnol Adv. 2014 Jul-Aug;32(4):778-88
pubmed: 24113214
Int J Nanomedicine. 2012;7:4099-107
pubmed: 22888246
PLoS One. 2013 Apr 17;8(4):e61853
pubmed: 23613954
Colloids Surf B Biointerfaces. 2021 Sep;205:111836
pubmed: 34058692